

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

MFE-280

RRID:CVCL_1405

Type: Cell Line

Proper Citation

RRID:CVCL_1405

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1405

Proper Citation: RRID:CVCL_1405

Description: Cell line MFE-280 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Endometrial adenocarcinoma

Defining Citation: [PMID:9615781](#), [PMID:9620227](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MFE-280

Synonyms: MFE 280, MFE280

Cross References: CLO:CLO_0007692, CLDB:cl5080, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:941, BioSample:SAMN03473586, BioSample:SAMN10987795, cancercellines:CVCL_1405, Cell_Model_Passport:SIDM00335, ChEMBL-Cells:ChEMBL3308455, ChEMBL-Targets:ChEMBL1075502, Cosmic:908129, Cosmic:1434185, Cosmic:1576462, Cosmic:2030478, Cosmic-CLP:908129, DepMap:ACH-000192, DSMZ:ACC-410, DSMZCellDive:ACC-410, ECACC:98050131,

EGA:EGAS00001000978, GDSC:908129, GEO:GSM374974, GEO:GSM375433, GEO:GSM844603, GEO:GSM887311, GEO:GSM888387, GEO:GSM1670098, IARC_TP53:21495, LiGeA:CCLE_689, LINCS_LDP:LCL-1500, PharmacDB:MFE280_919_2019, PRIDE:PXD030304, Progenetix:CVCL_1405, PubChem_Cell_line:CVCL_1405, Ubigen:YC-C101, Wikidata:Q54905380

ID: CVCL_1405

Record Creation Time: 20220427T220804+0000

Record Last Update: 20260920T004501+0000

Ratings and Alerts

No rating or validation information has been found for MFE-280.

No alerts have been found for MFE-280.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Khan S, et al. (2023) Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels. Cancers, 15(18).

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell reports, 42(11), 113352.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Molecular cancer therapeutics, 21(4), 635.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell, 81(4), 708.

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell reports. Medicine,

2(9), 100394.